30045-16-0
30045-16-0 結構式
基本信息
脫氫延胡索堿
去氫延胡索素
去氫延胡索甲素
脫氫紫堇堿(標準品)
去氫紫堇堿(標準品)
脫氫紫堇堿(去氫紫堇堿
去氫紫堇堿、去氫延胡索甲素
脫氫紫堇堿,去氫紫堇堿、去氫延胡索甲素
去氫紫堇堿,去氫延胡索甲素,去氫延胡索素
dehydeocorydaline
13-Methylpalmatine
DEHYDROCORYDALINE98%
5,6-Dihydro-2,3,9,10-tetramethoxy-13-methyldibenzo[a,g]quinolizinium
13-Methyl-2,3,9,10-tetramethoxy-5,6-dihydrodibenzo[a,g]quinolizinium
Dibenzo[a,g]quinolizinium,5,6-dihydro-2,3,9,10-tetramethoxy-13-methyl-
物理化學性質
| 報價日期 | 產品編號 | 產品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-N0674 | 去氫延胡索素 Dehydrocorydaline | 30045-16-0 | 1 mg | 533元 |
| 2026/06/05 | HY-N0674 | 去氫延胡索素 Dehydrocorydaline | 30045-16-0 | 5mg | 1400元 |
| 2026/06/05 | HY-N0674 | 去氫延胡索素 Dehydrocorydaline | 30045-16-0 | 10mM * 1mLin DMSO | 1540元 |
常見問題列表
|
Bcl-2
|
Bax
|
Caspase-7
|
Caspase-8
|
PARP
|
Dehydrocorydaline (0-200 μM) treatment significantly inhibits the growth of MCF-7 cells in a dose-dependent manner. The cell viability is decreased by approximate 40% after 24 h of 200 μM Dehydrocorydaline.
Dehydrocorydaline (0-200 μM)dose-dependently increases Bax protein expression and decreases Bcl-2 protein expression.
Dehydrocorydaline (0-200 μM)induces activation of caspase-7,-8 and the cleavage of PARP without affecting caspase-9.
Dehydrocorydaline manifests a low acute toxicity with an LD 50 of about 277.5±19.0 mg/kg body weight in mice following oral administration and 21.1±1.4 mg/kg for intraperitoneal injection.